Zhen Wang1, Ao-Mei Li1, Jie Gao1, Jing Li1, Bing Li1, Percy Lee2, Charles B Simone2, Yong Song3, Xi-Xu Zhu1. 1. Department of Radiation Oncology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China. 2. Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD 21201, USA. 3. Division of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Abstract
BACKGROUND: In certain situations, especially in the elderly patient population, a tissue diagnosis of a suspected pulmonary neoplasm is not feasible. Often, a definitive treatment such as stereotactic body radiosurgery is recommended, rather than active surveillance. The aim of this study is to evaluate the efficacy and tolerability of stereotactic body radiotherapy (SBRT) for elderly patients with presumed primary stage I lung cancer without pathological tissue confirmation. METHODS: We performed a retrospective analysis of 25 elderly patients (≥75 years) with presumed primary stage I lung cancer treated with SBRT from 2009-2015. The primary end point was local control (LC); secondary end points were survival and toxicity. RESULTS: The median follow-up (FU) was 36.0 months (range, 4 to 84 months). The 1-year LC rate was 100%, 3-year LC rate was 78.8%, and 5-year LC rate was 65.7%. The median progression-free survival (PFS) time was 48.0 months (95% CI: 31.2-64.8). The 1-, 3-, and 5-year overall survival (OS) rates were 96.0%, 70.2%, and 50.7%, respectively. The 1-, 3-, and 5-year cancer-specific survival (CSS) rates were 100%, 81.3%, and 67.0%, respectively. No grade 4 or higher toxicity was encountered. CONCLUSIONS: SBRT is safe and effective treatment for patients with presumed primary stage I lung cancer where obtaining pathological confirmation of malignancy is challenging.
BACKGROUND: In certain situations, especially in the elderly patient population, a tissue diagnosis of a suspected pulmonary neoplasm is not feasible. Often, a definitive treatment such as stereotactic body radiosurgery is recommended, rather than active surveillance. The aim of this study is to evaluate the efficacy and tolerability of stereotactic body radiotherapy (SBRT) for elderly patients with presumed primary stage I lung cancer without pathological tissue confirmation. METHODS: We performed a retrospective analysis of 25 elderly patients (≥75 years) with presumed primary stage I lung cancer treated with SBRT from 2009-2015. The primary end point was local control (LC); secondary end points were survival and toxicity. RESULTS: The median follow-up (FU) was 36.0 months (range, 4 to 84 months). The 1-year LC rate was 100%, 3-year LC rate was 78.8%, and 5-year LC rate was 65.7%. The median progression-free survival (PFS) time was 48.0 months (95% CI: 31.2-64.8). The 1-, 3-, and 5-year overall survival (OS) rates were 96.0%, 70.2%, and 50.7%, respectively. The 1-, 3-, and 5-year cancer-specific survival (CSS) rates were 100%, 81.3%, and 67.0%, respectively. No grade 4 or higher toxicity was encountered. CONCLUSIONS: SBRT is safe and effective treatment for patients with presumed primary stage I lung cancer where obtaining pathological confirmation of malignancy is challenging.
Entities:
Keywords:
Clinical diagnosis; elderly; stage I lung cancer; stereotactic ablative radiotherapy (SABR); stereotactic body radiotherapy (SBRT)
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Geoffrey A Geiger; Miranda B Kim; Eric P Xanthopoulos; Daniel A Pryma; Surbhi Grover; John P Plastaras; Corey J Langer; Charles B Simone; Ramesh Rengan Journal: Clin Lung Cancer Date: 2013-10-08 Impact factor: 4.785
Authors: Kevin L Stephans; Toufik Djemil; Chandana A Reddy; Stephen M Gajdos; Matthew Kolar; David Mason; Sudish Murthy; Thomas W Rice; Peter Mazzone; Michael Machuzak; Tarek Mekhail; Gregory M M Videtic Journal: J Thorac Oncol Date: 2009-08 Impact factor: 15.609
Authors: Ronica H Nanda; Yuan Liu; Theresa W Gillespie; John L Mikell; Suresh S Ramalingam; Felix G Fernandez; Walter J Curran; Joseph Lipscomb; Kristin A Higgins Journal: Cancer Date: 2015-09-08 Impact factor: 6.860
Authors: Roman O Kowalchuk; Michael R Waters; Sujith Baliga; K Martin Richardson; Kelly M Spencer; James M Larner; Charles R Kersh Journal: Transl Lung Cancer Res Date: 2020-10